Why the CRISPR Patent Verdict Isn’t the End of the Story
February 22, 2017
(Nature) – Berkeley filed for a patent earlier, but the USPTO granted the Broad’s patents first — and this week upheld them. There are high stakes involved in the ruling. The holder of key patents could make millions of dollars from CRISPR–Cas9’s applications in industry: already, the technique has speeded up genetic research, and scientists are using it to develop disease-resistant livestock and treatments for human diseases. But the fight for patent rights to CRISPR technology is by no means over. Here are four reasons why.